76K views · 235 reactions | Regular use of cannabis could increase an adolescent's likelihood of developing a psychiatric disorder, including schizophrenia. | NOVA l PBS | Facebook

Lead Story Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials Nature Medicine Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without mod